Photo Credit: Hailshadow
The following is a summary of “Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial,” published in the December 2024 issue of Psychiatry by Grilo et al.
Binge-eating disorder (BED) is a common and costly condition linked to significant functional impairments and comorbidities. Limited evidence-based treatments are available for BED.
Researchers conducted a retrospective study to evaluate the effectiveness of cognitive-behavioral therapy (CBT), lisdexamfetamine (LDX) and combined CBT+LDX for BED comorbid with obesity.
They conducted a randomized controlled trial from March 2019 to September 2023 at a single site with 141 patients with BED (83.7% women, mean age 43.6, mean BMI 38.6 kg/m2). Participants were randomized to 1 of 3 (12-week) treatments: CBT (N=47), LDX (N=47), or CBT+LDX (N=47), with 87.2% completing independent posttreatment assessments.
The results showed significant reductions in binge-eating frequency for all treatments, with CBT+LDX outperforming CBT and LDX. Binge-eating remission rates were 70.2% for CBT+LDX, 44.7% for CBT, and 40.4% for LDX. Weight loss increased in LDX and CBT+LDX, with both showing greater loss than CBT. ≥5% weight loss was achieved by 53.2% of LDX, 42.6% of CBT+LDX, and 4.3% of CBT. CBT+LDX also led to the most considerable reductions in eating disorder psychopathology.
They found that CBT, LDX, and CBT+LDX all significantly improved BED, with CBT+LDX showing the superior benefits.
Source: psychiatryonline.org/doi/10.1176/appi.ajp.20230982
